Google
BMY Stock Analysis — BRISTOL-MYERS SQUIBB COMPANY (Healthcare >> Drug Manufacturers - General)
BMY FAQ
What is BMY's P/E ratio?
BRISTOL-MYERS SQUIBB COMPANY (BMY) currently trades at a P/E ratio of 14.37.
What is BMY's ROE?
BRISTOL-MYERS SQUIBB COMPANY reports a Return on Equity (ROE) of 41.59%.
What is BMY's dividend yield?
BRISTOL-MYERS SQUIBB COMPANY offers a dividend yield of 3.87%.
What is BMY's Quality Score?
Our AI rates BMY's overall financial quality at 62 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy BMY?
Our AI Timing Score for BMY is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does BMY belong to?
BRISTOL-MYERS SQUIBB COMPANY is classified under the Healthcare >> Drug Manufacturers - General sector on the NYSE exchange
BMY AI Analysis Summary
Our AI summary for BMY: BRISTOL-MYERS SQUIBB COMPANY (NYSE), Healthcare >> Drug Manufacturers - General sector. The stock currently trades at a P/E of 14.37, ROE of 41.59%, a dividend yield of 3.87%. Its financial Quality Score stands at 62/100 — mid-range fundamentals relative to the market. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 65.31
Price
0.45
(0.69%)
Day Change
|
|
|---|
BMY, the overall quality is ok ( Quality = 62) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
Acceleration of ROE growth rate is below our criteria.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is good , ...
| Quality Factors |
|
50% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 90 |
| Magic Formula Rank by ROA |
718
|
| Magic Formula Rank by ROE |
718
|
| Magic Formula Rank by ROIC |
728
|
| Price | 65.31 |
| PBV / Sector |
5.98 / 2.68
|
| Earning Per Share | 4.55 |
| PE / Sector |
14.37 / 27.65
|
| PEG or PE/Growth / Sector |
-0.12 / 0.28
|
| Average 1M Daily Value |
563.28 M
|
| Average 1W Daily Value |
637.38 M
|
| Timing Factors |
|
85% |
| Financial Health |
|
47% |
| Ability to Make Profit |
|
70% |
| Return to Investors |
|
83% |
| Registration Details |
| Analyze Date | 2026-08-01 07:59:34 |
| Symbol | BMY |
| Name | BRISTOL-MYERS SQUIBB COMPANY |
| Sector | Healthcare >> Drug Manufacturers - General |
| Market | NYSE |
| Listed Shares | 2,042.07 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 133,367.67 / 256,404.20 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Route 206 & Province Line Road, Princeton, NJ, United States, 08543
Phone: 609 252 4621
Website: https://www.bms.com
Employees: 32,500
Description: Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - General
Click a bubble to view stock details · Bubble size represents market capitalization share
